Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Recombinant Human Anti‑Rabies Virus Monoclonal Antibody Injection in Healthy Adults
ChiCTR2600119961Phase 2Recruiting
- Sponsor
- Wuhan Jinyintan Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of recombinant human anti-rabies virus monoclonal antibody in rabies (7 arms), sponsored by Wuhan Jinyintan Hospital. Primary endpoints: Clinical observation indicators, Laboratory test indicators and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
recombinant human anti-rabies virus monoclonal antibody
03
Conditions
rabies
Beyond the preview
Go deeper on ChiCTR2600119961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119961.